Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.40 |
| ▸ | FEN1 | P39748 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | CHUK | O15111 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015953 | 1.00 | HTR1A (0.41) | HTR1ASLC6A2ALOX5APFEN1CHRNB2 | |
| SCHEMBL15605543 | 0.93 | HTR1A (0.41) | HTR1ASLC6A2CHRNB2CHRNA4 | |
| SCHEMBL14767784 | 0.93 | HTR1A (0.41) | HTR1ASLC6A2CHRNB2CHRNA4 | |
| SCHEMBL10257945 | 0.93 | HTR1A (0.41) | HTR1ASLC6A2CHRNB2CHRNA4 | |
| SCHEMBL2421529 | 0.88 | MCHR1 (0.41) | — | |
| SCHEMBL12322176 | 0.88 | MCHR1 (0.39) | — | |
| SCHEMBL2421021 | 0.87 | MCHR1 (0.43) | — | |
| SCHEMBL6015807 | 0.86 | HRH1 (0.41) | HTR1ASLC6A2ALOX5APFEN1KCNH2 | |
| SCHEMBL10258859 | 0.83 | IKBKB (0.41) | FEN1CHRNB2CHRNA4ROCK1ROCK2 | |
| SCHEMBL15567684 | 0.83 | IKBKB (0.41) | FEN1CHRNB2CHRNA4ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | FIREMENICH INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED | 2019-07-11 | — | — | US | disclosed |
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | SENOMYX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-2062050-B1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9181276-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150245642-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED | 2015-09-03 | — | — | US | disclosed |
| US-9000054-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | SENOMYX, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8633186-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC. (US) | 2014-01-21 | — | — | US | disclosed |
| WO-2013158928-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| EP-2573559-A1 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2568287-A2 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2012054526-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012021837-A2 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | SENOMYX, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2008154221-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | HTR1A 4395/4885SLC6A2 2256/4885ALOX5AP 3750/4885 |
| US-20150245642-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TFEB, TREH, SLC2A8 | HTR1A 4395/4885SLC6A2 2256/4885ALOX5AP 3750/4885 |
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | HTR1A 379/4885SLC6A2 1521/4885ALOX5AP 3828/4885 |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | HTR1A 4395/4885SLC6A2 2256/4885ALOX5AP 3750/4885 |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TFEB, TREH, SLC2A8 | HTR1A 4395/4885SLC6A2 2256/4885ALOX5AP 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.